Intellia Therapeutics
(NASDAQ:NTLA)
$48.365
-1.315[-2.65%]
Last update: 1:09PM (Delayed 15-Minutes)
Get Real Time Here
Day Range48.27 - 50.7252 Wk Range37.08 - 119.65Open / Close49.44 / -Float / Outstanding68.9M / 78.7M
Vol / Avg.196.9K / 999.9KMkt Cap3.8BP/E-50d Avg. Price53.89
Div / Yield-Payout Ratio-Total Float68.9MEPS-1.49

Intellia Therapeutics Stock (NASDAQ:NTLA), Quotes and News Summary

Intellia Therapeutics Stock (NASDAQ: NTLA) stock price, news, charts, stock research, profile.

Loading...
Day Range48.27 - 50.7252 Wk Range37.08 - 119.65Open / Close49.44 / -Float / Outstanding68.9M / 78.7M
Vol / Avg.196.9K / 999.9KMkt Cap3.8BP/E-50d Avg. Price53.89
Div / Yield-Payout Ratio-Total Float68.9MEPS-1.49
Seeking Alpha - Nov 13, 2022, 8:04PM
Seeking Alpha - Oct 24, 2022, 7:52PM
InvestorPlace - Sep 19, 2022, 4:30PM
Seeking Alpha - Sep 16, 2022, 12:16PM
Sector: Health Care.Industry: Biotechnology
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-02-23
REV
Q3 2022Est.ActualSurprise
EPS-1.280-1.490 -0.2100
REV11.310M13.266M1.956M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Intellia Therapeutics (NTLA) stock?

A

You can purchase shares of Intellia Therapeutics (NASDAQ: NTLA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Intellia Therapeutics's (NTLA) competitors?

Q

What is the target price for Intellia Therapeutics (NTLA) stock?

A

The latest price target for Intellia Therapeutics (NASDAQ: NTLA) was reported by Chardan Capital on Tuesday, November 15, 2022. The analyst firm set a price target for 129.00 expecting NTLA to rise to within 12 months (a possible 166.72% upside). 30 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Intellia Therapeutics (NTLA)?

A

The stock price for Intellia Therapeutics (NASDAQ: NTLA) is $48.365 last updated Today at November 28, 2022, 6:09 PM UTC.

Q

Does Intellia Therapeutics (NTLA) pay a dividend?

A

There are no upcoming dividends for Intellia Therapeutics.

Q

When is Intellia Therapeutics (NASDAQ:NTLA) reporting earnings?

A

Intellia Therapeutics’s Q4 earnings are confirmed for Thursday, February 23, 2023.

Q

Is Intellia Therapeutics (NTLA) going to split?

A

There is no upcoming split for Intellia Therapeutics.

Q

What sector and industry does Intellia Therapeutics (NTLA) operate in?

A

Intellia Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.